Perifosine

Search with Google Search with Bing

Information
Drug Name
Perifosine
Description
Entry(CIViC)
3
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
thyroid cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19706758 Detail
thyroid cancer PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19706758 Detail
thyroid cancer PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) 		D Predictive Supports Sensitivity/Response N/A 2 19706758 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Preclinical study in thyroid cancer cell lines. 6 ... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Preclinical study in thyroid cancer cell lines. 6 ... PIK3CA PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Preclinical study in thyroid cancer cell lines. 6 ... PTEN PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) 		Sensitivity true CIViC Evidence detail
Perifosine is an AKT inhibitor. Metastatic melanom... AKT1 AKT1 UNKNOWN Resitance or Non-Reponse true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT00498966 Completed Phase 2 Ph II Study of Perifosine for Patients With Carcinoma of the Kidney July 2007 October 2011
NCT00019656 Completed Phase 1 Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer August 1999
NCT00053781 Completed Phase 2 Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma June 20, 2003 December 21, 2009
NCT00053794 Completed Phase 2 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma June 9, 2003 September 22, 2008
NCT00053924 Completed Phase 2 Perifosine in Treating Patients With Advanced Pancreatic Cancer May 2003
NCT00054145 Completed Phase 2 Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer June 2003
NCT01097018 Completed Phase 3 Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer April 2010 April 2012
NCT01224730 Completed Phase 1 A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies January 24, 2012 November 4, 2013
NCT02238496 Completed Phase 1 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas December 8, 2014 February 14, 2021
NCT00059982 Completed Phase 2 Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer July 2003 August 2005
NCT00060437 Completed Phase 2 Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer October 2003 April 2004
NCT00064324 Completed Phase 2 Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma June 2003
NCT00301938 Completed Phase 1 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes December 2005
NCT00375791 Completed Phase 2 Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma December 2005 October 2011
NCT00389077 Completed Phase 2 Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas January 2005 September 2011
NCT00391560 Completed Phase 2 Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia October 2006 October 2011
NCT00398697 Completed Phase 1 Phase I Perifosine and Gemcitabine Study August 2004 January 2006
NCT00398710 Completed Phase 2 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia October 2006 October 2011
NCT00398814 Completed Phase 1 Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers October 2006 October 2011
NCT00398879 Completed Phase 2 Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients August 2005 October 2011
NCT00399087 Completed Phase 1 Phase I Trial of Docetaxel With Perifosine November 2004 January 2011
NCT00399126 Completed Phase 1 Phase I Trial of Paclitaxel With Perifosine November 2004 October 2011
NCT00399152 Completed Phase 1 Perifosine + Sunitinib Malate for Patients With Advanced Cancers October 2006 October 2009
NCT00399789 Completed Phase 1/Phase 2 A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer September 2004 December 2011
NCT00401011 Completed Phase 1/Phase 2 Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients August 2006 July 2011
NCT00401388 Completed Phase 2 A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas November 2006 October 2011
NCT00415064 Completed Phase 1 Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma December 2006 July 2012
NCT00422656 Completed Phase 2 Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia September 2006 November 2012
NCT00431054 Completed Phase 1 Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer February 2007 May 2012
NCT00448721 Completed Phase 2 A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer March 2007 October 2011
NCT00455559 Completed Phase 2 Ph II Study of Perifosine Plus Gleevec for Patients With GIST August 2006 October 2011
NCT00005794 Completed Phase 1 Perifosine in Treating Patients With Advanced Solid Tumors February 2000 July 2003
NCT00590954 Completed Phase 2 Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas May 2006 November 11, 2019
NCT00776867 Completed Phase 1 Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors October 2008 July 2017
NCT00847366 Completed N/A Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma May 2008 December 2012
NCT00873457 Completed Phase 2 Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma August 2009 April 2013
NCT01048580 Completed Phase 1 Study of Perifosine + Capecitabine for Colon Cancer Patients October 2009 October 2011
NCT01051557 Completed Phase 1/Phase 2 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma January 27, 2010 September 30, 2020
NCT00058214 Terminated Phase 2 Perifosine in Treating Patients With Recurrent Prostate Cancer March 2003 January 2009
NCT00062387 Terminated Phase 2 Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer May 2003 January 2007
NCT01002248 Terminated Phase 3 Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients December 2009 March 2013